With decentralized finance exploding in popularity, it only makes sense to look into the projects taking advantage of the movement to create income from crypto lending. One of those projects that has seen massively increased attention and growth in its token value is the Celsius Network, a crypto lending and wealth management platform based on crypto that […]
Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany), Mar 9, 2022 - (JCN Newswire) - NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.
Under the agreement, NOI will acquire VAXIMM's neoantigen vaccine-related patents, license the requisite manufacturing patents, and will take over several existing contracts with key collaborators and partners. Financial terms of the agreement have not been disclosed. In 2019, the companies entered into a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines. VAXIMM retains rights to its first-in-class oral T-cell activation platform technology and all other product candidates, including VXM01, which is being developed for the treatment of glioblastoma.
Commenting on the announcement, Richard Stratford, CEO of NOI, said, "We believe this is a transformative transaction for NOI/NEC. With it, NOI/NEC has acquired the rights to an attractive delivery platform with broad therapeutic potential in oncology and other areas. Following this acquisition, we expect to initiate the first clinical study delivering personalized neoantigens during 2022, which is an important milestone. Our unique artificial intelligence (AI) technology is focused on several attractive areas of unmet medical need with major market potential, and we now have the components in place to fully realize this significant commercial opportunity."
Thomas D. Szucs, MD, Chairman of the Board of VAXIMM, said, "I am excited to see the progress that has been made in advancing our neoantigen program, already with the strong support of NEC as partner and investor. I congratulate the VAXIMM team, under Dr. Lubenau's leadership, for bringing this important project to clinical testing stage. We are delighted that the NOI team will now take this program forward into the clinic with the goal of bringing a novel therapy to patients in desperate need of more treatment options."
Dr. Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through development and hopefully to the market to help patients. The first project from our earlier collaboration utilizing NEC's AI platform has received clinical trial approval in Europe, and we are excited that NEC will be putting its resources behind this and future neoantigen vaccine programs derived from VAXIMM's novel technology."
Motoo Nishihara, Executive Vice President, CTO (Chief Technology Officer) and Member of the Board, NEC Corporation, said, "Cancer and infectious diseases are two of the most serious healthcare challenges, with millions of new cases diagnosed worldwide annually. NEC's core AI technology is well positioned for the development of personalized medicines, and we are strongly committed to delivering effective treatments for cancer patients and infectious diseases. We are confident that this acquisition of assets from VAXIMM will enable us to further develop our AI-optimized and personalized therapies to benefit the health of individual patients worldwide."
The transaction expands NEC's neoantigen drug development pipeline by broadening its focus into several compelling therapeutic areas with high unmet medical need. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer vaccines and may overcome key challenges faced by many other approaches.
About NEC OncoImmunity AS
NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary machine learning-based software which addresses the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy, in addition to infectious disease vaccines. The AI technology can be used to identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable timeframe, and also facilitate effective patient selection for cancer immunotherapy. For more information, visit NEC OncoImmunity AS at http://www.oncoimmunity.com/.
NEC's neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T-cell response. With NEC OncoImmunity now onboard, NEC continues to strengthen its top class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide. For more information, visit NEC at www.nec.com.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM's plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients' cytotoxic T-cells to target a wide range of cancer-related antigens. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM has recently licensed its neoantigen program assets to NEC OncoImmunity, a subsidiary of NEC Corporation. VAXIMM's platform allows for fast manufacturing of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs.
VAXIMM's investors include: BB Biotech Ventures, BCM Europe, BioMedPartners, CMS, M Ventures, NEC and CSV as well as Sunstone Life Science Ventures. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company's development activities. For more information, please visit www.vaximm.com.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comNEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM's neoantigen program assets.
The Metaverse industry, in association with the non-fungible tokens (NFTs), has become one of the hottest tech sectors in recent months. Financial experts even projected that in the near future, the market valuation might be worth billions of dollars. Limitless potential, however, is a favorable point for cyber crime. For the first time in history, [...]
Welcome, Cryptonaut, to the world of tomorrow. The year is 2089. Wait, or is it 2090? Heck, who even remembers years anymore. It is late in the 21st century anyway. Earth is a dystopian place, and world governments and countries have collapsed. Humanity is ruled by corporations and franchises, and the planet is plunged into […]
Tokyo, Japan and San Jose, Calif, Feb 28, 2022 - (ACN Newswire) - Rakuten Symphony, Inc. today announced an agreement to acquire leading Silicon Valley-based cloud technology start-up, Robin.io. The addition of Robin.io's multi-cloud mobility, hyper automation and orchestration capabilities to the Rakuten Symphony portfolio allows the creation of highly efficient, consistent high performance cloud infrastructure and operations, from edge to central data center.
Collaboration between Rakuten and Robin.io has already been underway for more than two years, since Rakuten Mobile leveraged Robin.io in production for the Japan deployment of the world's first end-to-end fully virtualized cloud-native mobile network*1. Understanding the high performance requirements of mobile radio and network applications, combined with the need for financial efficiency and automated operation for scale, enabled Rakuten Mobile and Robin.io to create a complete cloud-native offering to deliver and manage the most demanding applications of this and the next era. Now, Rakuten Symphony and Robin.io are coming together to further accelerate and strengthen the complete end to end automated cloud offering for customers across the globe.
"Edge cloud requirements are unique and critical as mobile operators transition to 5G: The next era of digital experience requires another level of performance, responsiveness and consistency that enables telecom operator and enterprise transformation to be safely accelerated while creating a platform to support the next 10 years of experiences. Robin.io's cloud capability is proven to be effective for the most demanding workloads in mobile and we believe it will allow Rakuten Symphony to safely accelerate cloud-native transformation for our customers and prepare the industry for the future," said Tareq Amin, CEO, Rakuten Symphony. "We plan to continue to invest into Robin.io's cloud-native portfolio of products to further advance our capabilities and offer the most advanced and highly integrated cloud platform mobile operators demand."
"I am delighted that Robin.io's technology innovations over the last several years will now get a much bigger canvas to lead the vision for cloud-native transformation for the industry. Our vision to deliver simple to use, easy to deploy hyperscale automation is very well aligned," said Partha Seetala, CEO, Robin.io. "We believe Robin.io's customers will hugely benefit from the synergies of cloud-native technology innovations from Robin.io, and the open competitive infrastructure solutions and global scale of Rakuten Symphony. This is indeed an exciting phase for us as we work together to bring a much larger ecosystem together to deliver higher value for our customers globally."
With over 70 patents in the cloud-native technology space, Robin.io offers a highly differentiated and comprehensive product portfolio, including the following:
Robin Cloud Native Storage (Robin CNS) - An award winning, high performing, software-defined and industry-first application-aware storage solution that has been built from the ground-up for Kubernetes.
Robin Cloud Native Platform (CNP) - A leading open-source platform optimized for running data and network intensive applications used in production for various use cases involving databases, big data, data analytics, 5G, O-RAN, packet core & edge.
Robin.io has petabyte size deployments with its software running on tens of thousands of servers in production today that span across its product portfolio and services Fortune 1000 customers across the Americas, Europe and Asia.
Adding Robin.io's portfolio for cloud-native deployment, lifecycle management and orchestration allows Rakuten Symphony to deploy highly reliable, flexible, scalable, secure and resilient mobile networks built on the principles of open interfaces, virtualization and interoperability. Together, the combined companies will also be able to deliver industry leading solutions for various traditional enterprise opportunities in areas of enterprise applications, data management, cloud and virtualization. Following the acquisition, Partha Seetala will take up the position of President of the Unified Cloud business unit of Rakuten Symphony.
The transaction is subject to closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. The terms of the acquisition are confidential.
*1 For a large scale commercial mobile network (as of October 1, 2019). Research: Stella Associate
About Rakuten Symphony
Rakuten Symphony is reimagining telecom, changing supply chain norms and disrupting outmoded thinking that threatens the industry's pursuit of rapid innovation and growth. Based on proven modern infrastructure practices, its open interface platforms make it possible to launch and operate advanced mobile services in a fraction of the time and cost of conventional approaches, with no compromise to network quality or security. Rakuten Symphony has headquarters in Japan and local presence in the United States, Singapore, India, Europe and the Middle East Africa region. For more information, visit: https://symphony.rakuten.com/
Robin.io provides cloud-native capabilities that automate deployment, scaling and lifecycle management of enterprise and 5G applications on Kubernetes. The company's core technology uses application bundles and application pipelines, which are automated through patented infrastructure and application-topology awareness technology. Robin.io allows developers and platform engineers to deploy and easily manage data rapidly- and network-centric applications—including big data, NoSQL and 5G—independent of underlying infrastructure resources.
Headquartered in Silicon Valley, California, Robin.io solutions are recognized by Gartner, IDC, GigaOm and others for their innovation and reliability. More at www.robin.io and Twitter: @robin4K8S.
SAN JOSE, CA, Feb 25, 2022 - (ACN Newswire) -Robin.io, the world's leading provider of Cloud Native Platform for Service Providers is participating at the world's most influential event, Mobile World Congress - Barcelona, 2022. At MWC #2022, Robin.io and industry-leading partners aim to demonstrate to customers live use cases and future-ready stack on the new capabilities of 5G and Edge.
Communication Service Providers (CSPs) and Mobile Network Operators (MNOs) are facing huge 5G investment decisions over the next few years. Robin Cloud-native, flexible Kubernetes platform offers greater choice and agility to accelerate new connectivity and service options. Robin.io is already helping operators provide the 5G/MEC service promise with unmatched lifecycle simplicity, performance, scale, and advanced workload placement.
Mobile network operators (MNOs) are building their 5G network infrastructure with a new emphasis on cost effective performance. Robin.io is able to quickly bring their platform to deployment and also support 5G vRAN by using Intel Smart Edge – a cloud native based software platform that incorporates advanced Kubernetes networking for Telco deployment, real-time optimizations, 5G acceleration in FPGA or eASIC form factor, orchestration support, advanced observability, and also supports ORAN RIC use cases. Robin.io, as a Titanium level partner at Intel Network Builders Winners' Circle, has incorporated Intel Smart Edge Open technology in our platform, running Cloud-Native Open RAN and Edge in production today. Robin.io will showcase 5G, ORAN & Edge use cases and demos, running on 3rd Gen Intel Xeon Scalable processors, at MWC.
Partha Seetela, CEO Robin.io, said, "Operators and Enterprises alike are embarking on a path to modernization and containerization of the 5G services including Open Radio Access Networks (O-RAN), Mobile Edge Computing (MEC) and Packet Core. Robin.io will accelerate these transformations and modernizations. We are excited to collaborate with our ecosystem of partner companies to automate service delivery of integrated Network services and solutions. We are showcasing these solutions with our partners at MWC #2022."
"The alliance with Robin.io enables us to provide CSPs with a differentiated cloud-native services portfolio. Multi-cloud orchestration, metal to service orchestration and management, and network function orchestration and management with a faster go-to-market approach are key to success," said Rajiv Papneja, Head of Cloud & Network Services at Prodapt.
Robin.io has also partnered with industry-leading technology companies including QCT, Lekha Wireless, Blue Arcus, Kloudspot and 6wind that drive innovation across the enterprise and Telco markets. The collaboration aims to build a seamless automated cloud-native platform that brings a new level of automation and efficiency reducing infrastructure and operation costs and minimizing deployment time which boost the time-to-market of diverse 5G services and applications.
Mike Yang, President of QCT, said, "By partnering with Robin.io, we are modernizing 5G solutions and giving our mutual customers improved performance. This partnership significantly reduces the development time for Systems Integrators, CSPs and other strategic alliances by enabling a smooth path to integration and orchestration, which eases the cost and operational effort needed for productization."
Ramu Srinivasaiah, CoFounder & Director of Lekha Wireless, said, "This collaboration enables us to deliver a turnkey solution to the private enterprise market. As we embark on this journey to integrate the network elements with Robin.io along with Blue Arcus, I see it is a unique partnership that can deliver a much-needed disaggregated 5G network to the market."
Naren Yanamadala, CEO & Founder of Blue Arcus, commented, "We are excited about our partnership with Robin.io as this is an important milestone achieved as part of the collaboration initiated to address the 5G enterprise use cases."
Blue Arcus offers a cloud-native 5G core, providing a reliable, scalable, and distributed autonomous network solution that helps mobile network operators and system integrators build their solutions to deploy IoT, Private/Enterprise Networks, MEC networks.
Mehran Hadipour, Vice President of Business Development and Tech Alliances, said, "Intelligent infrastructure and automation technologies is key consideration as the industry prepare to deploy 5G and Edge services along with Open Radio Access Networks (O-RAN), Robin.io working with our partners will enable the industry and operators to deliver a significant number of new services with increased speed and lower latency and reduced cost with strict Quality of Service (QoS). Robin.io, along with partners, will bring cloud agility to deploy 4G and 5G RAN (DU, CU, Radio Controller), AMF, UPF, etc., on COTS hardware. Our joint solution brings centralized orchestration and automates deployment in minutes while allowing scaling to a million nodes and automating lifecycle management tasks."
Harnessing data-driven digital solutions for CSPs, Ravi Akireddy – Founder & CEO, Kloudspot said, "Kloudspot is a cloud-agnostic Location and Situational Awareness and Location Analytics platform that rides on the Network edge infrastructure. Using AI and ML, Kloudspot will provide experiential insights and report into a lifestyle, workspace, health and safety, asset and infrastructure utilization for customers."
Julien Dahan, CEO, 6WIND stated, "Our collaboration with Robin.io gives CSPs and Cloud Providers the option to deploy our Cloud-Native Virtual Service Router (VSR) solutions on Robin's platform. 6WIND provides cloud-native VSR network solutions that deliver the performance and scalability needed by CSPs to fully unleash their agility and flexibility in defining innovative edge and core services, fully automated and dynamically adapted to evolving requirements. We are excited to partner with Robin.io, as we are able to jointly address CSPs and deliver best-of-breed solutions, including among others, a virtual security Gateway (vSecGW), a virtual Provider Edge Router (vPE), a virtual CG-NAT router (vCG-NAT), a virtual Cell Site Router (vCSR), that accelerate the 5G and Edge deployments".
Robin.io embraces Cloud-Native technology standard deployments for 5G with significant economic and operational benefits for the operators.
Robin.io, the 5G and application automation platform company, delivers products that automate the deployment, scaling and life cycle management of data- and network-intensive applications and for 5G service chains across the edge, core and RAN. The Robin platform is used globally by companies including BNP Paribas, Palo Alto Networks, Rakuten Mobile, SAP, Sabre and USA. Robin.io is headquartered in Silicon Valley, California. More at http://www.robin.io and Twitter: @robin4K8S
Prodapt has a singular focus on the Connectedness vertical. Prodapt's customers range from telecom operators, digital / multi-service providers (D/MSPs), technology and digital platform companies in the business of connectedness. Prodapt builds, integrates, and operates solutions enabling next-generation technologies and innovations. Prodapt works with global leaders including AT&T, Verizon, Lumen, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, Deutsche Telekom among many others. Prodapt's customers today help more than a billion people, and five billion devices stay connected. Prodapt has offices in North America, Europe, Latam, India, and Africa. It is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
QCT is a global provider of data center products, including servers, storage and networking equipment as well as configuration and support services. The company targets midsize and large enterprise data center customers, service providers and governments who want the engineering excellence of a global manufacturer of integrated data center solutions, but do not require the scale and resources of a full-service original design manufacturer. Each product in the QCT lineup is specifically engineered for a different function in the data center. This eliminates the need for over-engineering and excessive feature sets that often plague conventional equipment with unnecessary cost and complexity. As a result, QCT products measurably outperform conventional designs in energy consumption, cooling efficiency, acquisition cost (CAPEX) and operational expense (OPEX). Based in San Jose California, QCT LLC is a subsidiary of Fortune Global 500 Company, Quanta Computer Inc.
Lekha Wireless Solutions Pvt. Ltd. is a Bengaluru based deep tech company in wireless telecom and defence communication. Started in the year 2010, we are a team of 200+ Engineers, with leadership team comprising of telecom experts with over 2 decades of experience in end-to-end product development and deployment. We are OEM for Telecom RAN infrastructure products, SDR Products and we License Protocol Software Stacks for 4G and 5G. We have filed/received multiple patents in 4G, 5G and Industrial communication technologies.
Blue Arcus is a global end-to-end 4G/5G mobile network software provider, delivering telecom solutions that are 3GPP compliant and built on an open and distributed architecture.
With many live deployments across Pacific, Asia, Middle East and Africa, we have been helping MNOs enhance customer experience by providing cost-effective, fast, and reliable voice and data services. The SMART Compact network edge of core makes it suitable for providing high speed, secure and low-latency services.
Pioneering the future of work transformation, Kloudspot embraces hybrid work options, enabling employees to determine their optimal space to think, collaborate and create. The future of work will be fluid: physical, digital, or an immersive virtual blend of both. Using sophisticated IoT data management, machine learning, and AI, Kloudspot understands the intersection of space, time, and action so that businesses can anticipate and deliver inspiring spaces for employees and customers anytime, anywhere. Headquartered at Sunnyvale, California, customers use Kloudspot hybrid work management solutions to successfully enable connected in-person and virtual on-and-off premise work while helping to assure health and safety as their offices have re-opened.
6WIND is a virtualized networking software company and the worldwide market leader for Virtual Service Router solutions. 6WIND software is deployed globally by Service Providers, Cloud Providers, Enterprises, Systems Integrators, and Tier-1 OEMs, allowing customers to replace expensive hardware with software and virtualization for routing and security use cases. 6WIND has a global presence with Headquarters based in Paris, France and in Santa Clara, California.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com
INTERNET CITY, DUBAI, Feb. 23, 2022 – LBank Exchange, a global digital asset trading platform, will list EYES Protocol (EYES) on February 25, 2022. For all users of LBank Exchange, the EYES/USDT trading pair will be officially available for trading at 18:00 (UTC+8) on February 25, 2022. It has become more important than ever to...
HONG KONG, Feb 23, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today, under the stock code of 2157 and in board lot of 1,000 H shares each.
The share price of the Company closed at HK$7.14 per H share, with an intra-day high of HK$7.34 per H share. A total of approximately 15.8 million H shares were traded, with an aggregate turnover of approximately HK$112 million.
Lepu Biopharma is listed on the main board of HKEX, with 126,876,000 H shares being offered globally, including 12,688,000 Hong Kong Offer Shares, 114,188,000 International Placing Shares. The net proceeds received are estimated at approximately HK$804.2 million from the Global Offering, after deduction of underwriting fees, commissions and other estimated expenses payable by the Company in connection with the Global Offering. The net proceeds are intended for funding the core products, funding the other key clinical-stage drug candidates and the key pre-clinical drug candidates, acquiring potential technologies and assets and expand our pipeline of drug candidates, including discovery of new drug candidates and business development activities and to fulfill the continuous payment obligation under the acquisition of HX008 from HanX, and general corporate purposes.
Lepu Biopharma has three synergistic core technology platforms around its pipeline specializing in ADC technology, antibody discovery and advanced process and analytical development. The company also advances the clinical development of its candidates including ADC candidates, oncolytic virus candidates and combination therapies, plans to stay focused on the development of innovative products, create a pipeline for novel therapies, design and develop innovative products and build advanced technology platforms.
While Lepu Biopharma advancing its drug candidates, it has mapped out and is implementing the manufacturing and commercialization strategies. Company commenced the operation of a 2,000L GMP-compliant antibody production line in Beijing in 2019 in support of clinical trials for the antibody products. It is building a production line for oncolytic virus drugs in Beijing with a designed capacity of 200L, as well as a biologics manufacturing center in Shanghai Biotech Park, including a production line with a designed capacity of 12,000L initially, coupled with laboratories and manufacturing facilities, and one production line with capacity of 6,000L under construction.
The Founder, Chairman and Executive Director of Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie said, "Today, we are very delighted to witness Lepu Biopharma to be officially listed on the Hong Kong Stock Exchange. This is an important milestone in our history of development as well as a starting point of our new journey. We sincerely appreciated the long-term trust and cooperation from customers and shareholders. We would also like to thank our partners, the Hong Kong Stock Exchange and the Securities and Futures Commission for all the great support. With solid R&D capabilities, advanced development platforms and comprehensive pipeline, we will seize the future trend of the whole industry, strengthen our position in the market with our competitive advantages and create greater value for shareholders and investors."
About Lepu Biopharma Co., Ltd.
Lepu Biopharma was incorporated in 2018 and is a biopharmaceutical company focusing on oncology therapeutics. The Company has designed pipeline with a range of oncology products. As of [the Latest Practicable Date], the Company had pipeline including eight clinical-stage drug candidates, three pre-clinical drug candidates and three clinical-stage combination therapies of the candidates in the pipeline. In addition, the Company focus on the development of innovative drugs including ADC and oncolytic virus. According to Frost & Sullivan, the Company house the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates. As of [the Latest Practicable Date], the Company had initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S. In terms of patents, as of [the Latest Practicable Date], Company had 11 issued patents in China, 20 in the U.S., nine in Japan, seven in the European Union and one in each of South Korea, Australia, Chile, India, Colombia, Indonesia, New Zealand and Israel, and 74 pending patent applications, consisting of 15 in Mainland China and 59 in overseas jurisdictions such as the U.S., Japan, India, South Korea, Australia, Israel, India and the European Union. Patentportfolio of the Company spans across mAb structure, targeted epitope, CMC, usage, biopharmaceutical formulation and indications.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today
Meta works on a new deal with Brazil to trademark crypto and is awaiting the green light for an application registration with the Brazilian authorities that will allow for a further expansion on the market so let’s read furhter in today’s latest cryptocurrency news. Meta published the application for registration and is currently awaiting opposition […]